Harrow, Inc.
NASDAQHarrow, Inc. heads into the back half of 2026 with a striking split in conviction — the co-founders bought the stock aggressively after a steep earnings selloff, while short sellers have quietly added to already elevated positions. The insider buying is the sharpest signal from the past month. After HROW fell roughly 22% following its Q1 earnings print on May 12…
Snapshot as of 28 Jun 2026
Harrow, Inc. heads into the back half of 2026 with a striking split in conviction — the co-founders bought the stock aggressively after a steep earnings selloff, while short sellers have quietly added to already…
HROW entered its Q1 print as one of the most shorted small-cap pharma names on Nasdaq. The stock's 24% collapse confirms that heavy positioning wasn't misplaced. Harrow reported Q1 results after the close on May 11.…
Harrow, Inc. heads into its Q1 2026 earnings today with a short book that remains stubbornly elevated — and a stock that has pulled back sharply from this year's highs. Short sellers are not backing down. At 17% of the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for HROW — free to start on ORTEX.
Sign up for free →Open HROW on ORTEX